Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 1:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 2,691 matching trials from the live ClinicalTrials.gov search.
Recruiting Phase 2 Interventional Accepts healthy volunteers

Feasibility Study for Fibroblast Autologous Skin Grafts

NCT01964859
Conditions
Wounds and Injuries
Interventions
autologous skin fibroblasts, Filler Product
Biological
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Renal Cell Carcinoma
Interventions
DC RCC-RNA
Biological
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Anaplastic Large Cell Lymphoma, ALK-Negative, Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Best Practice, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, High Dose Chemotherapy, Leukapheresis, Positron Emission Tomography, Stem Cell Mobilization Therapy
Procedure · Other · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 75 Years
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2075
U.S. locations
164
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 123 more
Conditions
Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis, SLE Nephritis, ANCA Associated Vasculitis
Interventions
KYV-101, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
David Porter
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
High Risk Newly Diagnosed Multiple Myeloma
Interventions
Bispecific Monoclonal Antibody and Triplet Therapy, Monoclonal Antibody with Stem Cell Transplant
Drug
Lead sponsor
Multiple Myeloma Research Consortium
Network
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
12
States / cities
Duarte, California • Atlanta, Georgia • Chicago, Illinois + 8 more
Conditions
Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Angioimmunoblastic T-Cell Lymphoma, Ann Arbor Stage II Noncutaneous Anaplastic Large Cell Lymphoma, Ann Arbor Stage III Noncutaneous Anaplastic Large Cell Lymphoma, Ann Arbor Stage IV Noncutaneous Anaplastic Large Cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Hepatosplenic T-Cell Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions
Brentuximab Vedotin, Cyclophosphamide, Doxorubicin, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, Laboratory Biomarker Analysis, Prednisone
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
4
States / cities
Duarte, California • Hackensack, New Jersey • Columbus, Ohio + 1 more
Conditions
Radiculopathy, Herniated Disc, Disc Degeneration
Interventions
Regenexx PL-Disc, Steroid Epidural
Procedure
Lead sponsor
Regenexx, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Broomfield, Colorado
Conditions
Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma
Interventions
therapeutic autologous lymphocytes, aldesleukin, denileukin diftitox, biopsy, immunohistochemistry staining method, laboratory biomarker analysis, polymerase chain reaction
Biological · Procedure · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Leukemia
Interventions
therapeutic autologous lymphocytes, cyclophosphamide
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Prostate Cancer
Interventions
Autologous dendritic cells transfected with amplified tumor RNA
Biological
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Durham, North Carolina
Active, not recruiting Phase 2 Interventional Results available

KRDI in Transplant-Eligible MM

NCT04430894
Conditions
Multiple Myeloma
Interventions
Carfilzomib, Isatuximab, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts
Conditions
Lymphoma
Interventions
Carmustine, Etoposide, Cytarabine, Melphalan, Rituximab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 80 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Houston, Texas
Conditions
Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Recurrent Acute Lymphoblastic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myeloid Leukemia, BCR-ABL1 Positive, Recurrent Indolent Non-Hodgkin Lymphoma, Recurrent Lymphoblastic Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myeloid Leukemia, BCR-ABL1 Positive, Refractory Indolent Non-Hodgkin Lymphoma, Refractory Lymphoblastic Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Transformed Chronic Lymphocytic Leukemia
Interventions
Autologous Anti-CD19/CD20/CD22 CAR T-cells, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Echocardiography Test, Fludarabine, Multigated Acquisition Scan, Pheresis, Positron Emission Tomography
Biological · Procedure · Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Columbus, Ohio
Terminated Phase 1 Interventional Accepts healthy volunteers

Collagen Injections for the Treatment of Acne Scars and Wrinkles

NCT01704209
Conditions
Acne Scars, Wrinkles
Interventions
Fibroblast Treatment, Vehicle
Drug · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Severe Combined Immunodeficiency
Interventions
AProArt-CD34, CliniMACS® CD34 Reagent System cell sorter device, Busulfan
Drug · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
2 Months and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2038
U.S. locations
1
States / cities
San Francisco, California
Conditions
Multiple Myeloma
Interventions
Biospecimen Collection, Dietary Intervention, Medical Chart Review, Questionnaire Administration
Procedure · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Idiopathic Pulmonary Fibrosis and Progressive Fibrotic Interstitial Lung Disease
Interventions
Lung Spheroid Stem Cells 100 million, Lung Spheroid Stem Cells 200 million
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
40 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Mantle Cell Lymphoma
Interventions
bortezomib
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 69 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2022
U.S. locations
48
States / cities
San Francisco, California • Bloomington, Illinois • Canton, Illinois + 26 more
Conditions
Classic Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Interventions
Brentuximab Vedotin, Laboratory Biomarker Analysis, Nivolumab
Drug · Other · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
6
States / cities
Duarte, California • Rochester, Minnesota • Hackensack, New Jersey + 3 more
Conditions
Sickle Cell Disease
Interventions
OTQ923
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 40 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Chicago, Illinois • New York, New York • Memphis, Tennessee
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Platelet-rich Plasma (PRP) for Endometrial Regeneration and Repair

NCT02825849
Conditions
Infertility, Asherman's Syndrome
Interventions
Intrauterine infusion of platelet rich plasma
Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 43 Years · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
San Francisco, California
Conditions
RHEUMATOID ARTHRITIS
Interventions
Immune ablation and hematopoietic stem cell transplant
Biological
Lead sponsor
Richard Burt, MD
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Breast Cancer
Interventions
filgrastim, peripheral blood stem cell transplantation, yttrium Y 90 monoclonal antibody B3
Biological · Procedure · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
2
States / cities
Bethesda, Maryland
Conditions
Perianal Fistula
Interventions
Only 1 arm: treatment with MSC-AFP
Drug
Lead sponsor
William A. Faubion, M.D.
Other
Eligibility
12 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota